Epstein Files Search

EFTA00596397Set 9

49p11,093w

International Diabetes Federation Report on the International Insulin and Diabetes Supplies Survey on Cost and Availability 2006 Task Force on Insulin, Test Strips and Other Diabetes Supplies EFTA00596397 Table ... Introduction 5 2. Methodology 6 Limitations 6 3. Findings 8 3.1.1 Access to insulin 8 3.1.2 Reasons for lack of access to insulin 9 3.1.3 People who require insulin ... cannot obtain it 10 3.1.4 Taxes on insulin 11 3.1.5 Provision of insulin free or at subsidized prices 12 3.1.6 Where insulin can be bought 12 3.1.7 Cost

https://www.justice.gov/epstein/files/DataSet%209/EFTA00596397.pdf

EFTA00753606Set 9

49p11,069w

International Diabetes Federation Report on the International Insulin and Diabetes Supplies Survey on Cost and Availability 2006 Task Force on Insulin, Test Strips and Other Diabetes Supplies EFTA00753606 Table ... Introduction 5 2. Methodology 6 Limitations 6 3. Findings 8 3.1.1 Access to insulin 8 3.1.2 Reasons for lack of access to insulin 9 3.1.3 People who require insulin ... cannot obtain it 10 3.1.4 Taxes on insulin 11 3.1.5 Provision of insulin free or at subsidized prices 12 3.1.6 Where insulin can be bought 12 3.1.7 Cost

https://www.justice.gov/epstein/files/DataSet%209/EFTA00753606.pdf

EFTA00620069Set 9

26p10,915w

above. Rather, I believe this risk is driven by hyperinsulinemia and a condition called insulin resistance—the reduced capacity for our cells to dispose of glucose in response to insulin ... Indeed, obesity is a proxy for this state—two-thirds of obese individuals are insulin resistant—however nearly 10% of lean individuals are also insulin _5_ EFTA00620073 resistant. A number ... field have been become increasingly critical of this distinction between obesity and insulin resistance. Streamlining this a bit further, once you've reached your 40s and 50s, and assuming

https://www.justice.gov/epstein/files/DataSet%209/EFTA00620069.pdf

EFTA00596375Set 9

2010-02-178p1,168w

Insulin Opportunity: Technical Presentation PR IUM 3Mr FUN IVDS ac EFTA00596375 Patent Portfolio Patent Estate There is a solid IP Portfolio for the regular insulin process Intellectual Property Portfolio Title ... Methods for • 343445-00006 • 61.305.451 • 2/17/2010 • Provisional App.; To Preparation convert on 2/17/2011 Insulin Production Methods and • 343445-00005 • 7,790.677 • 5/20/2007(FD) • Issued Pro-Insulin Constructs • 9/7/2010 ... Maintenance Fee due 3/7/2014 Insulin Production Methods and • 343445-00013 • 12/658,852 • 2/16/2010 • Continuation of Pro-Insulin Constructs 11/715.731 • Published 8/19/2010 Improved Insulin Aspart Analog • 343445-00014 • TBD • In progress

https://www.justice.gov/epstein/files/DataSet%209/EFTA00596375.pdf

EFTA00753773Set 9

2010-11-014p2,137w

real possibility of high reward even based on this very limited information. 1) Insulin market is very competitive with many very well funded players looking at biosimilar and bio- same ... insulin a. There are 3 major players who control the insulin market on a branded basis, and only one real competitor generically (but that competitor is not a true generic ... patent protection for our true generic process leading to the first economically feasible generic insulin without supply constraints. Thus, we are not entering a crowded market since this

https://www.justice.gov/epstein/files/DataSet%209/EFTA00753773.pdf

EFTA00777553Set 9

2010-11-015p2,328w

real possibility of high reward even based on this very limited information. 1) Insulin market is very competitive with many very well funded players looking at biosimilar and bio- same ... insulin a. There are 3 major players who control the insulin market on a branded basis, and only one real competitor generically (but that competitor is not a true generic ... patent protection for our true generic process leading to the first economically feasible generic insulin without supply constraints. Thus, we are not entering a crowded market since this

https://www.justice.gov/epstein/files/DataSet%209/EFTA00777553.pdf

EFTA00828851Set 9

2016-04-2440p12,929w

metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin ... cost $245 billion in 2012 1) Type 1 diabetes The body does not produce insulin. Some people may refer to this type as insulin-dependent diabetes, juvenile diabetes, or early ... diabetes cases are type 1. Patients with type 1 diabetes will need to take insulin injections for the rest of their life. They must also ensure proper blood-glucose levels

https://www.justice.gov/epstein/files/DataSet%209/EFTA00828851.pdf

EFTA00753599Set 9

7p1,105w

Global Insulin Opportunity a generic solution to supply constraints ERivium At FUNDS lac EFTA00753599 Special Note Regarding Forward Looking Statements Preface This presentation includes forward-looking statements within the meaning ... OTHER THAN EVALUATING A POTENTIAL INVESTMENT IN THE COMPANY. 2 l FUNDSm„c EFTA00753600 Insulin Pricing Can be Undercut by up to 50% Strategic Overview By leveraging a unique manufacturing ... global marketplace Strategic Overview • Become renowned for making available the purest form of insulin to the widest number of users in target countries worldwide, offering it through the most convenient

https://www.justice.gov/epstein/files/DataSet%209/EFTA00753599.pdf

EFTA00596368Set 9

7p1,105w

Global Insulin Opportunity a generic solution to supply constraints ERivium At FUNDS lac EFTA00596368 Special Note Regarding Forward Looking Statements Preface This presentation includes forward-looking statements within the meaning ... OTHER THAN EVALUATING A POTENTIAL INVESTMENT IN THE COMPANY. 2 l FUNDSm„c EFTA00596369 Insulin Pricing Can be Undercut by up to 50% Strategic Overview By leveraging a unique manufacturing ... global marketplace Strategic Overview • Become renowned for making available the purest form of insulin to the widest number of users in target countries worldwide, offering it through the most convenient

https://www.justice.gov/epstein/files/DataSet%209/EFTA00596368.pdf

EFTA00625612Set 9

2017-01-2931p11,722w

damage to the eyes. Diabetes is due to either the pancreas not producing enough insulin or the cells of the body not responding properly to the insulin produced. There ... mellitus: - Type 1 DM results from the pancreas's failure to produce enough EFTA00625624 insulin. This form was previously referred to as "insulin-dependent diabetes mellitus" (IDDM) or "juvenile diabetes ... cause is unknown. - Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin

https://www.justice.gov/epstein/files/DataSet%209/EFTA00625612.pdf

EFTA00596383Set 9

14p4,018w

group of diseases marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes can lead to serious complications and premature death ... lower the risk of complications. Types of diabetes Type 1 diabetes was previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. Type 1 diabetes develops when the body ... destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. To survive, people with type 1 diabetes must have insulin delivered

https://www.justice.gov/epstein/files/DataSet%209/EFTA00596383.pdf

EFTA01115268Set 9

3p1,537w

diabetes and how the disease was invariably fatal until Sir Frederick Banting discovered insulin in 1922. The discovery of insulin was a dramatic breakthrough that saved millions of lives ... transformed the disease from fatal to a chronic condition requiring life-long insulin replacement therapies. I will share photos' and stories of the historic events of insulin discovery and early ... insulin use. I will then review the post-insulin era, and how we realized that conventional insulin therapy is insufficient and that patients would still develop long term devastating complications

https://www.justice.gov/epstein/files/DataSet%209/EFTA01115268.pdf

EFTA00138991Set 9

2019-08-10148p32,818w

Sleep apnea, G4730 - Current PLAN: New Medication Orders: Eta Medication Order Date Prescriber Order INsulin REG - Human 07/30/2019 15:58 SLIDING SCALE Subcutaneously each morning x 7 day(s) Pill ... Only Indication: Prediabetes Discontinued Medication Orders: Eta Medication Order Date Prescriber Order 122148-NYM Insulin Reg (10 ML) 100 UNITS/ML lnj 07/30/2019 15:58 Inject regular insulin subcutaneously per sliding ... Orally • Two Times a MG/5ML Day PRN x 90 day(s) Indication: Constipation, unspecified INsulin REG - Human 07/30/2019 11:12 SLIDING SCALE Subcutaneously • Two Times

https://www.justice.gov/epstein/files/DataSet%209/EFTA00138991.pdf

EFTA00127743Set 9

2019-01-2765p26,235w

confined to their cells. MDC Brooklyn's Health Services staff deliver required medication or insulin to inmates every morning and evening. Inmates line up in their housing unit common area ... their cells. Staff and inmates refer to these deliveries as "pill line" and "insulin line." Pill line and insulin line may occur simultaneously or at different times, meaning that Health ... written request or ask Health Services staff for a refill during pill or insulin line. Inmates in the SHU are confined to their cells for 23 hours

https://www.justice.gov/epstein/files/DataSet%209/EFTA00127743.pdf

EFTA01214751Set 9

2016-12-0118p2,555w

Sender: Participants: ( ), Self ( jeeitunes®gmail.com ) Alzheimer as a type of insulin resistance for neurons is really interesting. You don't have to have systemic diabetes or insulin challenges but somehow ... Sender: ( Participants: ( ), Self ( e:jeeitunes@gmail.com ) Alzheimer as a type of insulin resistance for neurons is really interesting. You don't have to have systemic diabetes or insulin challenges but somehow ... EFTA01214763 Sender: Participants: ), Self ( e: ) Alzheimer as a type of insulin resistance for neurons is really interesting. You don't have to have systemic diabetes or insulin challenges but somehow

https://www.justice.gov/epstein/files/DataSet%209/EFTA01214751.pdf

EFTA00073831Set 9

2019-08-10149p34,214w

Medication Orders: Withheld pursuant to exemption Rxtl Medication Order Date Prescriber Order INsulin REG - Human (b)(8); (b)(dXM10;/0)(g)11%)58 SLIDING SCALE Subcutaneously each morning ... Only Indication: Prediabetes Discontinued Medication Orders: Rx# Medication Order Date Prescriber Order 122148-NYM Insulin Reg (10 ML) 100 UNITSML lnj 07/30/2019 15:58 Inject regular insulin subcutaneously per sliding ... Orally - Two Times a MG15ML Day PRN x 90 day(s) Indication: Constipation. unspecified INsulin REG - Human 07/30/2019 11:12 SLIDING SCALE Subcutaneously - Two Times

https://www.justice.gov/epstein/files/DataSet%209/EFTA00073831.pdf

EFTA01091480Set 9

2014-12-0511p3,697w

03/2012 - 06/2012 Claire Duval, pharmacy visiting student, Universite de Nantes, France Project: Pharmacokinetics of insulin and glucagon during closed-loop operation in type 1 diabetes. Refereed Journal Publications: [9] Other ... Approach to Diabetes Research and Clinical Translation, Dasman Diabetes Center, Kuwait Title: Glucose-Responsive Insulin and Glucagon Delivery to Regulate Glucose Levels in Type 1 Diabetes 05/2012 University of Montreal ... Temple, DB Dunger, A Haidar, M Nodale, ME Wilinska and R Hovorka. Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1Diabetes. Diabetes care

https://www.justice.gov/epstein/files/DataSet%209/EFTA01091480.pdf

EFTA00753594Set 9

2010-10-292p573w

From: "Wayne Holman" > To: "Jeffrey Epstein" <jeevacation@gmail.com> Subject: RE: FW: Insulin Information Date: Fri, 29 Oct 2010 20:28:54 +0000 Hi Jeffrey, This looks extremely high risk and without ... real possibility of high reward even based on this very limited information. 1) Insulin market is very competitive with many very well funded players looking at biosimilar and bio- same ... insulin 2) These guys are very early - recent IND approval from US FDA means they are not in human trials yet or just started very recently though I suspect

https://www.justice.gov/epstein/files/DataSet%209/EFTA00753594.pdf

EFTA00777763Set 9

2010-10-293p749w

From: Jeffrey Epstein To: Wayne Holman Subject: Re: FW: Insulin Information Date: Fri, 29 Oct 2010 20:40:37 +0000 well done.. thanks ... real possibility of high reward even based on this very limited information. 1) Insulin market is very competitive with many very well funded players looking at biosimilar and bio-same ... insulin 2) These guys are very early - recent IND approval from US FDA means they are not in human trials yet or just started very recently though I suspect

https://www.justice.gov/epstein/files/DataSet%209/EFTA00777763.pdf

EFTA00105002Set 9

2019-07-09101p14,860w

Orig Entered: 07/09/2019 12:51 EST Blood Glucose: Date Time Value Imaldll Tyoe Regular Insulin provider 08/04/2019 08:30 156 Non-Fasting Orig Entered: 08/04/2019 ... 07/10/19 PRN 1421 Wort nqutc. Insulin stPcutrrtoousty per Exp. Dab acting 44,4J: Nrka (14'4 —•44:1 Ilnr for 7 07/31419 days 1001 NYM 122146- NYA4 tni.0 ... Doctor: Exp: 01/13/20 Pharmacy DispensIngs: 180 Cap in 24 days Start: 07/17/19 Insulin Reg (10 ML) 100 UNITS/ML Inj daily "'pill line*" for 7 days morn line*" Inject regular Insulin

https://www.justice.gov/epstein/files/DataSet%209/EFTA00105002.pdf